药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Podofilox
Encorafenib
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Encorafenib.
Podofilox
Dexverapamil
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Dexverapamil.
Podofilox
Penfluridol
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Penfluridol.
Podofilox
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Dexchlorpheniramine.
Podofilox
Lorcainide
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Lorcainide.
Podofilox
Bunaftine
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Bunaftine.
Podofilox
Nizofenone
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Nizofenone.
Podofilox
Otilonium
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Otilonium.
Podofilox
Sultopride
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Sultopride.
Podofilox
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Sitafloxacin.
Podofilox
Oxatomide
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Oxatomide.
Podofilox
Abexinostat
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Abexinostat.
Podofilox
Mizolastine
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Mizolastine.
Podofilox
Ricolinostat
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Ricolinostat.
Podofilox
Simendan
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Simendan.
Podofilox
CUDC-101
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with CUDC-101.
Podofilox
Entinostat
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Entinostat.
Podofilox
Mocetinostat
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Mocetinostat.
Podofilox
Amifampridine
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Amifampridine.
Podofilox
Dexchlorpheniramine maleate
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Dexchlorpheniramine maleate.